Patient Stories
FILTER BY TESTS
Melanoma diagnosis, now what?
Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.
From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis
Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.
Don't let fear define your journey: a uveal melanoma patient journey
Danet didn’t let fear of the unknown define her uveal melanoma journey. Hear how Castle Biosciences DecisionDx-UM test impacted her treatment.
Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story
As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.
Castle Biosciences: Our Story
A closer look into Castle Biosciences: our 'why,' the mission driving our company, and the incredible people dedicated to improving patient care each and every day.
CDO - Highly Accurate & Objective Tests for Melanocytic Lesions of Uncertain Malignant Potential
DecisionDx®-Melanoma Helps to Guide Patient Management Decisions
Dr. Aaron Farberg speaks about how the DecisionDx-Melanoma test results helps better identify a patient's risk of metastasis and how some patients may be able to forgo a SLNB procedure.
DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients
Dr. Clay Cockerell speaks on how the DecisionDx-Melanoma test is not intended to replace staging systems but how using GEP can increase risk prediction for patients with Stage I-III melanoma.
Interview and Research Highlights with Dr. Jacques Bergman
Dr. Bergman (Amsterdam University Medical Centers) discusses his latest research into tools for risk stratification of patients with community-based diagnosis of low-grade dysplasia.